North America’s pharma industry saw a drop of 4.8% in deal activity during March 2019, when compared with the last 12-month average, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 80 pharma industry deals worth $4.53bn were announced for the region in March 2019, against the 12-month average of 84 deals.
Of all the deal types, venture financing saw most activity in March 2019 with 61 transactions, representing a 76.3% share for the region.
In second place was M&A with 17 deals, followed by private equity deals with two transactions, respectively capturing a 21.3% and 2.5% share of the overall deal activity for the month.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn terms of value of deals, M&A was the leading category in North America’s pharma industry with $3.53bn, while venture financing and private equity deals totalled $833.44m and $171.2m, respectively.
North America pharma industry deals in March 2019: Top deals
The top five pharma deals accounted for 79.7% of the overall value during March 2019.
The combined value of the top five pharma deals stood at $3.61bn, against the overall value of $4.53bn recorded for the month. The top announced pharma deal tracked by GlobalData in March 2019 was Thermo Fisher Scientific‘s $1.7bn acquisition of Brammer Bio.
In second place was the $827m asset transaction with Ligand Pharmaceuticals by RP Management and in third place was Smith & Nephew’s $660.5m acquisition of Osiris Therapeutics.
The $280m merger of Scilex Pharmaceuticals and Semnur Pharmaceuticals and Athyrium Capital Management’s private equity deal with Secura Bio for $145m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
